Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies

Regulations by 2FIRSTS.ai
Jun.24.2024
Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies
Australia government withdraws e-cigarette sales plan, allowing non-prescription purchase at pharmacies. Health Minister Mark Butler reached agreement with Greens.

According to The Sydney Morning Herald on June 24th, the Australian government has withdrawn its plan to allow e-cigarettes to be sold commercially. E-cigarettes will not require a prescription to be purchased in pharmacies.

 

Minister of Health Mark Butler reached an agreement with the Green Party on Monday, June 24th, to relax the ban on e-cigarettes scheduled to take effect in July. This was in order to pass legislation in the Senate to prohibit retail sales, as the initially stricter proposal did not have the support of the majority of senators.

 

According to sources familiar with the agreement, after the ban on e-cigarettes takes effect in July, consumers will still need a doctor's prescription to purchase e-cigarettes. However, in the future, adults will not need a prescription from a general practitioner to buy e-cigarettes from pharmacies. They will only need to speak with a pharmacist and can purchase them over the counter.

 

At the same time, individuals under the age of 18 are allowed to purchase e-cigarettes with a prescription from a clinician if deemed appropriate.

 

The government has promised to provide additional funding to support young people in quitting e-cigarettes.

 

E-cigarettes sold in pharmacies will still be regulated and must comply with standard packaging requirements.

 

Butler's adjustment is a concession to the substantial political capital invested in the success of the e-cigarette ban. He will announce the full details of the changes later today.

 

Butler previously proposed the idea of allowing people to purchase e-cigarettes from pharmacies without a prescription, but he stated that this would only be considered if the prescription drug model is not successful.

 

He stated in November of last year,

 

Health ministers are interested in exploring whether e-cigarettes can be provided solely by pharmacists in pharmacies, where similar products are often located behind the counter and require interaction with a pharmacist but not a doctor's prescription.

 

We have not made a decision yet, but I have said that if the proposed reform does not adequately ensure that people with genuine treatment needs can access e-cigarettes, we will consider other options.

 

Both the Greens and the National Party have expressed doubt about the proposal put forward by the Labor Party to ban all retail sales of e-cigarettes and require a prescription from a general practitioner to obtain them from a pharmacy. This is a stricter version of the law first proposed by former Coalition Health Minister Greg Hunt in 2021.

 

The Green Party and the two major political parties are aligned in their desire to prevent children from purchasing e-cigarettes from unlicensed stores.

 

However, the Greens' health spokesperson, Jordon Steele-John, expressed concerns about the difficulties and costs of quitting smoking for those who need to make an appointment with a general practitioner in order to get a prescription. The Department of Health's analysis of Butler's original plan indicates that 450,000 Australians per year will seek e-cigarette prescriptions, requiring nearly one million visits to general practitioners.

 

John also expressed skepticism towards the prohibition model, pointing out that drug bans have proven to be ineffective.

 

Many young Australians are using e-cigarettes, banning the sale of e-cigarettes could potentially become a political issue.

 

No one should be punished for personal use of e-cigarettes. Prohibition policies for drugs have failed. Many people under the age of 18 are becoming addicted to nicotine. We need to ensure there are proper resources in place to help these individuals quit using e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
In an interview with Romanian marketing publication IQads, Marek Gębski, Director of Smoke-Free Products at Philip Morris Romania, said IQOS experience spaces are evolving from traditional retail locations into platforms for consumer engagement and brand connection. Through locations such as IQOS Boutique Victoriei, PMI aims to use design, culture and consumer experiences to strengthen communication with adult consumers about smoke-free products. The interview highlights how tobacco companies are expanding smoke-free strategies beyond products toward experiential marketing and consumer relationships.
Aug.11
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05